Ionis Delays Cash-Flow Breakeven To 2029 And Cuts Tringolza Forecast To About $50 Million

Physician interest has been slower to become paid treatment, while trial setbacks also pushed back the cash-flow target.

Share
Ionis Delays Cash-Flow Breakeven To 2029 And Cuts Tringolza Forecast To About $50 Million

Ionis Pharmaceuticals, which develops RNA-targeted medicines for serious diseases, pushed its expected cash-flow breakeven to 2029 from 2028 and cut its full-year Tringolza sales forecast to approximately $50 million on Monday's earnings call. Chief Financial Officer Beth Hougen attributed the delay to recent late-stage trial setbacks and a “slower than anticipated Tringolza launch.”

Enthusiasm Hasn't Become Paid Treatment

Tringolza generated $9 million in third-quarter sales, its first full quarter after June approval for severe hypertriglyceridemia — very high triglyceride levels — and $41 million for the year to date. Chief Executive Officer Brett Monia said the broader launch requires physicians to change how they treat patients: "Tringolza requires HCPs to adopt a new approach to patient care, which takes time."

A Jefferies analyst questioned why management's positive comments about July and August contrasted with the forecast cut. Monia said the early assessment drew on physician interest, rather than patients successfully reaching insured treatment. "Now we just have to bring these patients through and get them onto covered drug."

Chief Global Product Strategy Officer Kyle Genet said approximately 1,500 physicians had prescribed Tringolza through September, but only approximately 24% had written repeat prescriptions. Doctors often want to observe an initial patient's response before treating others. Some require 10-plus sales-team visits, covering patient selection, the medicine and reimbursement, before prescribing.

Ionis is increasing contact with priority doctors and helping practices navigate insurance requirements. Its couple hundred sales representatives reach about 20,000 cardiologists, endocrinologists and lipid specialists, compared with about 3,000 physicians for its narrower FCS launch.

Free Starts, Broader Insurance Coverage

Most early prescriptions required an exception to insurers' usual coverage rules. By September's end, plans representing 33% of commercially insured lives had added the broader indication to their covered-drug lists. Current policies cover adults with triglyceride levels of at least 500 milligrams per deciliter, beyond Ionis' initial high-risk focus.

The expanded Quick Start program supplies free medicine while coverage is arranged. Hougen said the revised sales outlook accounts for that expansion; revenue follows when patients move onto paid therapy. Genet expects the program to continue, alongside the Ionis EveryStep patient-support service, four specialty pharmacies and a field team helping offices secure reimbursement.

Management still projects more than $3 billion in peak annual Tringolza sales. Genet cited more than 3 million U.S. patients with severe hypertriglyceridemia, including approximately 1 million at high risk. He also pointed to trial results showing placebo-adjusted triglyceride reductions of up to 72% and acute pancreatitis event reductions of up to 91%, plus monthly self-administered dosing.

Other Revenue Keeps Guidance Intact

The commercial slowdown comes against a difficult backdrop. Novartis announced in September that pelacarsen failed its late-stage trial, a setback for the heart-disease program partnered with Ionis in 2019. Before the earnings report, Ionis shares had lost about 50% since the start of 2026. IONS shares plunged about 28% to $28.28 in Monday trading.

Ionis combines medicines it sells itself with partner revenue. Its portfolio includes TRYNGOLZA and DAWNZERA, which it sells in the U.S., and WAINUA, co-commercialized there with AstraZeneca. Neurology and cardiometabolic diseases are central to its development business.

Total third-quarter revenue was $243 million, with commercial revenue of $136 million exceeding research-and-development revenue. The product transcribed as Donzera generated $37 million in quarterly sales and $79 million year to date. Management maintained total 2026 revenue guidance of $875 million to $900 million and an adjusted operating-loss forecast of $425 million to $475 million.

Ionis ended the quarter with $1.9 billion in cash and investments and expects more than $1.6 billion at year-end. Hougen said the company would assess financing needs while weighing capital costs and dilution as it continues investing in launches and its pipeline.

Hougen plans to provide 2027 guidance at the February year-end earnings call, when management will set its next revenue expectations for the launch.

Sources

More on Ionis Pharmaceuticals

All Ionis Pharmaceuticals (IONS) coverage →